Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel

Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractPurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) systemic treatments were...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
There has been no recent randomized evidence justifying postoperative radiation therapy (PORT) in patients with non-small cell lung cancer who have undergone complete resection; it is not recommended for routine use, even in patients with mediastinal involvement (pN2).1,2 Adjuvant treatments such as chemotherapy and PORT should be discussed at a multidisciplinary board with complete surgical and pathologic reports, checking whether the nodal exploration was appropriate, the location and number of mediastinal nodes and hilar/intrapulmonary nodes that were resected, and whether resection was complete.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Condition:   NSCLC Interventions:   Drug: Kanglaite Injection+Chemotherapy;   Drug: Chemotherapy Sponsors:   Jie Li;   Ministry of Science and Technology of the People´s Republic of China;   Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer. DOI: 10.3779/j.issn.1009-3419.2019.06.08
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
We report one effective individual case that ado pted pemetrexed re-challenge strategy in advanced NSCLC for three times, and at the same time conduct the relevant literature review. DOI: 10.3779/j.issn.1009-3419.2019.06.11
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Authors: Rocco D, Della Gravara L, Battiloro C, Gridelli C Abstract Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorable results- in order to increase the PFS and OS rates of these patients. Areas covered: Therefore, this paper aims to discuss the most promising trials investigating chemo-immunotherapy combinations and their present and future impact ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Conclusions: A cisplatin-HOXB13-ABCG1/EZH2/Slug network may account for a novel mechanism underlying cisplatin resistance and metastasis after chemotherapy. Determining the levels of HOXB13 and its target genes from needle biopsy specimens may help predict the sensitivity of lung adenocarcinoma patients to platinum-based chemotherapy and patient outcomes.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusions: Our study demonstrated that regimens with VEGFR-TKIs combined with chemotherapy improved PFS, ORR and DCR in patients with advanced NSCLC, but had no impact on OS. VEGFR-TKIs induced more frequent and serious AEs compared with control therapies.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
This study aimed to investigate whether P16 methylation could be used to predict paclitaxel chemosensitivity of NSCLC. Advanced NSCLC (N=45) were obtained from patients who were enrolled in a phase-III randomized paclitaxel-based clinical trial. Genomic DNA samples were extracted from the biopsies prior to chemotherapy. P16 methylation was detected using MethyLight. The association between P16 methylation and the sensitivity of paclitaxel in cell lines was determined by in vitro assay using a P16-specific DNA demethylase (P16-TET) and methyltransferase (P16-Dnmt). The total response rate of the low-dose paclitaxel-based ch...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
This study investigated the ability of the ferritin-to-hemoglobin ratio to predict survival in patients with advanced non-small-cell lung cancer (NSCLC).Methods: The medical records of patients with pathologically confirmed advanced NSCLC were retrospectively reviewed. The ferritin level, hemoglobin level, and ferritin-to-hemoglobin ratio at the initiation of treatment were investigated. After descriptive analysis of the ferritin-to-hemoglobin ratio, the optimal diagnostic cutoff value for survival was determined using receiver operating characteristic analysis. After dichotomizing patients according to the optimal cutoff ...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Study